Quetiapine prolonged-release tablets (Seroquel XL®) are recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults.
In order to limit errors, prolonged-release quetiapine should be prescribed by brand name, as Seroquel XL®. AWMSG is of the opinion that quetiapine prolonged-release tablets (Seroquel XL®) may be suitable for shared care within NHS Wales.
Quetiapine prolonged-release tablets (Seroquel XL®) are not endorsed for the treatment of manic episodes associated with bipolar disorder within NHS Wales. AstraZeneca UK Ltd is not in a position to progress a submission to AWMSG for its appraisal in this indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.